News about "ENFLONSIA clesrovimab approval"

European Commission Approves Merck's ENFLONSIA Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants

European Commission Approves Merck's ENFLONSIA Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants

Merck receives European Commission approval for ENFLONSIA (clesrovimab), a novel RSV preventive therapy for infants, designed to protect against lower respiratory tract disease during their first RSV season.

ENFLONSIA Clesrovimab Approval | 20/04/2026 | By News Bureau


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members